Search

Learn how to keep your immune system balanced.

… Wednesday, December 22, 2021 You may have read articles or seen products that claim to “boost” your immune system. But what does that mean — and is it even the right goal? Contrary to popular belief, our bodies don’t have one singular immune system. The immune system is actually made up of many different

In 2024, the MSK Giving community raised $511 million to advance MSK’s mission of ending cancer for life — every single dollar donated is making a real difference in the way we treat and understand cancer.

… Friday, June 6, 2025 In 2024, we invited the MSK Giving community to join an ambitious effort to raise $6 billion by 2030 and shape the future of cancer care — The MSK Campaign: Leading Science. Changing Lives .  In response, MSK donors contributed $511 million to advance MSK’s mission of ending cancer

Developmental biologist Maria Jasin studies homologous recombination, which is important in DNA repair and can lead to cancer when it malfunctions.

… Friday, July 1, 2011 Summary Developmental biologist Maria Jasin studies homologous recombination, which is important in DNA repair and can lead to cancer when it malfunctions. When chromosomes are copied and divided faithfully and no DNA damage is passed on, a parent cell gives rise to two identical

Our research shows that most women diagnosed with either breast or gynecologic cancer have concerns about how treatment may affect their sexual and vaginal health. Moreover, they want their healthcare providers to initiate the discussion.

… Friday, November 10, 2017 Our research shows that most women diagnosed with either breast or gynecologic cancer have concerns about how treatment may affect their sexual and vaginal health. Moreover, they want their healthcare providers to initiate the discussion. At Memorial Sloan Kettering Cancer Center

Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has been elected to the National Academy of Medicine (NAM), one of the most prestigious honors in the fields of health and medicine.

… Monday, October 20, 2025 Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has been elected to the National

In mice, drugs that change the way proteins are assembled appear to make checkpoint inhibitor drugs work better.

… Thursday, June 24, 2021 Like an invading army, cancer cells can have different modes of action. Some announce their arrival loudly while others wreak havoc by sneaking under the radar. Immunotherapy drugs called checkpoint inhibitors work best against the less stealthy type. Their role is to take the

Results from the first phase I clinical trial of a new drug were presented at the American Association for Cancer Research’s meeting.

… Monday, April 1, 2019 Summary Early findings from the first phase I clinical trial of a drug called LOXO-195 were presented at the American Association for Cancer Research’s annual meeting in Atlanta. In November 2018, the US Food and Drug Administration approved the targeted therapy larotrectinib (Vitrakvi

Scientists have long known that cancer cells and immune cells have an uncommon hunger for glucose but haven’t understood why. A new study offers an answer.

… Thursday, January 21, 2021 Summary A long-standing mystery is why fast-growing cells, like cancer cells and immune cells, rely on a seemingly inefficient form of metabolizing glucose to power their activities. In a new study, scientists at the Sloan Kettering Institute offer a compelling solution. The

New MSK research provides two examples of computational tools developed at MSK that leverage data about cells’ locations to expand our understanding of cancer.

… Friday, April 26, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) provides two examples of computational tools developed at MSK that leverage data about cells’ locations to expand our understanding of cancer. One approach describes cellular “neighborhoods” not just in terms of which

This is the second regulatory approval of the cell-based immunotherapy for a blood cancer.

… Thursday, October 19, 2017 Summary People with an aggressive form of lymphoma that is no longer responding to chemotherapy may now be eligible to receive a novel cell-based immunotherapy called CAR T . Previously, this treatment was available only to people participating in clinical trials . For the